脑转移瘤合理治疗模式的Meta分析

摘要/Abstract

摘要：目的应用Meta分析的方法探讨脑转移瘤的合理治疗模式。方法以中英文关键词检索中外数据库，检索时限为自各数据库建立起至2012年12月30日。以Jadad评分评价文献质量，采用RevMan5.0软件完成统计分析。共纳入25篇文献，2 750例患者，依据不同的治疗方法进行分组。结果与单一治疗相比，综合治疗能提高患者的1年生存率（OR=0.58，95%CI为0.46~0.71，P＜0.000 01）；在综合治疗组中，与2种联合治疗方式相比，3种联合治疗方式能提高患者的1年生存率（OR=0.63，95%CI为0.50~0.80，P=0.000 1）；与局部治疗相比，全身+局部治疗能提高患者的1年生存率（OR=0.68，95%CI为0.53~0.86，P=0.001）；与全身治疗相比，全身+局部治疗能提高患者的1年生存率（OR=0.59，95%CI为0.41~0.86，P=0.006）；在全身+局部治疗中，与2种联合治疗方式相比，3种联合治疗方式能提高患者的1年生存率（OR=0.52，95%CI为0.35~0.78，P=0.002）；与非靶向治疗相比，分子靶向药物治疗能提高患者的1年生存率（OR=0.76，95%CI为0.67~0.87，P＜0.000 1）。结论脑转移瘤的合理治疗模式为手术、放疗、化疗3种治疗方式结合，即全身+局部治疗，如果具有应用分子靶向药物的指征，在原方案基础上联合分子靶向药物效果更佳。

关键词:Meta分析,肿瘤治疗方案,存活率,脑转移

Abstract:ObjectiveTo explore the ideal treatment mode of brain metastases by Metaanalysis. MethodsArticles were searched for from the databases at home and abroad using English and Chinese keywords. Searching time limited from the databases setting up to December 30, 2012. Jadad score was applied to evaluate the qualities of literatures. RevMan5.0 software was applied to perform the Metaanalysis. A totle of 25 articles including 2 750 patients were eligible for the Metaanalysis, which divided into groups with different treatment. ResultsCompared with monotherapy, combined therapy improved 1year survival (OR=0.58, 95%CI： 0.46~0.71， P＜0.000 01). In combined therapy groups, compared with two methods, three kinds of therapies improved 1year survival (OR=0.63, 95%CI： 0.50~0.80， P=0.000 1). Compared with local therapy only or systemic therapy only, systemic combined local therapy improved 1year survival (OR=0.68, 95%CI： 0.53~0.86， P=0.001; OR=0.59, 95%CI： 0.41~0.86， P=0.006). In systemic combined local therapy groups, three kinds of treatments improved 1year survival compared with two methods (OR=0.52, 95%CI： 0.35~0.78， P=0.002). Compared with nonmolecular targeted therapy, molecular targeted therapy improved 1year survival (OR=0.76, 95%CI： 0.67~0.87， P＜0.000 1). ConclusionThe reasonable treatment for patients with brain metastases is combined treatment with operation, radiotherapy and chemotherapy. There is better curative effect added molecular targeted therapy based on original scheme, if patients have targeted therapy indications.

Key words:Meta-analysis,Antineoplastic protocols,Survival rate,Brain metastases

李颖,房晓萌,姜达,董倩,张增叶,郑飞. 脑转移瘤合理治疗模式的Meta分析[J]. 国际肿瘤学杂志, 2015, 42(2): 103-108.

Li Ying, Fang Xiaomeng, Jiang Da, Dong Qian, Zhang Zengye, Zheng Fei. Meta analysis of brain metastases ideal treatment mode[J]. Journal of International Oncology, 2015, 42(2): 103-108.

参考文献

［1］ Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology［J］. J Neurooncol, 2005, 75(1): 5-14. ［2］ Fabi A, Felici A, Metro G, et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center［J］. J Exp Clin Cancer Res, 2011, 30: 10. ［3］ Antonadou D, Paraskevaidis M, Sarris G, et al. Phase Ⅱ randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases［J］. J Clin Oncol, 2002, 20(17): 3644-3650. ［4］ Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebralmetastasis［J］. Cancer, 1996, 78(7): 1470-1476. ［5］ Postmus PE, HaaxmaReiche H, Smit EF, et al. Treatment of brain metastases of smallcell lung cancer: comparing teniposide and teniposide with wholebrain radiotherapy a phase Ⅲ study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group［J］. J Clin Oncol, 2000, 18(19): 3400-3408. ［6］ Chua D, Krzakowski M, Chouaid C, et al. Wholebrain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from nonsmallcell lung cancer: a randomized, openlabel phase Ⅱ study［J］. Clin Lung Cancer, 2010, 11(3): 176-181. ［7］董丽华, 刘军, 刘锋. 非小细胞肺癌脑转移综合治疗的探讨［J］. 中风与神经疾病杂志, 2005, 22(4): 362. ［8］马明, 赵建, 王中彬. 非小细胞肺癌脑转移的治疗［J］. 辽宁医学院学报, 2007, 28(2): 40-42. ［9］ Guerrieri M, Wong K, Ryan G, et al. A randomized phase Ⅲ study of palliative radiation with concomitant carboplatin for brain metastases from nonsmall cell carcinoma of the lung［J］. Lung Cancer, 2004, 46(1): 107-111. ［10］ Le Scodan R, Jouanneau L, Massard C, et al. Brain metastases from breast cancer: prognostic significance of HER2 overexpression, effect of trastuzumab and cause of death［J］. BMC Cancer, 2011, 11: 395. ［11］石玉生, 张兴梅. 163例脑转移瘤疗效分析［J］. 第一军医大学学报, 1999, 19 (3): 269-271. ［12］ Neuhaus T, Ko Y, Muller RP, et al. A phase Ⅲ trial of topotecan and whole brain radiation therapy for patients with CNSmetastases due to lung cancer［J］. Br J Cancer, 2009, 100(2): 291-297. ［13］夏建洪, 陈立春, 乔岩, 等. 替加氟同步放疗治疗消化道肿瘤脑转移效果观察［J］. 武警医学, 2012, 23(7): 580-583. ［14］ Zeng YD, Zhang L, Liao H, et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from nonsmallcell lung cancer: a retrospective study［J］. Asian Pac J Cancer Prev, 2012, 13(3): 909-914. ［15］于永江, 刘穗媛. 脑转移瘤治疗方法的选择和疗效分析［J］. 中国现代医生, 2009, 47(32): 14-15. ［16］梁艺湖, 麦洁文. 不同方法治疗脑转移瘤5l例疗效分析［J］. 广东医学院学报, 2000, 18(1): 102-104. ［17］张东兴, 卢宜民. 放射治疗联合拓朴替康治疗肺癌脑转移34例［J］. 中国实用医刊, 2011, 38(19): 99-101. ［18］张湘衡, 夏云飞, 牟永告, 等. 168例脑转移瘤病例分析［J］. 广东医学, 2002, 23(1): 12-13. ［19］董明新, 赵彤, 黄京子, 等. 非小细胞肺癌脑转移瘤治疗方案的优化选择［J］. 中华放射医学与防护杂志, 2006, 26(4): 371-373. ［20］何安泰. 肺癌脑转移患者长期生存分析［J］. 中国厂矿医, 2008, 21(6): 649-651. ［21］周忠清, 梁冶矢, 张劲松, 等. 脑转移瘤的外科治疗［J］. 医师进修杂志, 2004, 27(10): 15-17. ［22］乔建. 脑转移瘤120例诊治分析［J］. 陕西医学杂志, 2006, 35(9): 1102-1105. ［23］ Kim KH, Lee J, Lee JI, et al. Can upfront systemic chemotherapy replace stereotactic radio surgery or whole brain radiotherapy in the treatment of nonsmall cell lung cancer patients with asymptomatic brain metastases［J］. Lung Cancer, 2010, 68(2): 258-263. ［24］鲁继斌, 苏守元. 肺癌脑转移140例临床资料分析［J］. 中国肿瘤临床, 1993, 20(4): 269-272. ［25］ Sandler A, Gray R, Perry MC, et al. Paclitaxelcarboplatin alone or with bevacizumab for nonsmallcell lung cancer［J］. N Engl J Med, 2006, 355(24): 2542-2550. ［26］黄忠连, 杨震, 李超. 非小细胞肺癌脑转移放射治疗的预后因素分析［J］. 安徽医药, 2012, 16(8): 1136-1139. ［27］黄福献, 郑艳, 买买提江·卡斯木, 等. 颅内转移瘤患者不同个体化治疗方案疗效比较［J］. 吉林大学学报, 2013, 39(4): 828-831. ［28］ Garber ST, Jensen RL. Image guidance for brain metastases resection［J］. Surg Neurol Int, 2012, 3 Suppl 2: S111-117. ［29］ Welsh JW, Komaki R, Amini A, et al. Phase Ⅱ trial of erlotinib plus concurrent wholebrain radiation therapy for patients with brain metastases from nonsmallcell lung cancer［J］. J Clin Oncol, 2013, 31(7): 895-902.

[1]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛.铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[2]	赵永瑞, 高莹, 陈怡东, 徐建堃.基于直线加速器的分次立体定向放疗对小体积脑转移瘤的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 138-143.
[3]	孙晓琳, 张展昱, 许林宗, 刘英超, 李晓梅.放疗联合免疫治疗在乳腺癌脑转移瘤中的潜在价值[J]. 国际肿瘤学杂志, 2022, 49(4): 243-246.
[4]	纪环, 周菊英, 马辰莺, 徐晓婷, 秦颂兵.非小细胞肺癌脑转移的放疗进展[J]. 国际肿瘤学杂志, 2022, 49(3): 181-184.
[5]	中国医师协会放射肿瘤治疗医师分会.脑转移瘤立体定向放射治疗临床指南[J]. 国际肿瘤学杂志, 2021, 48(8): 456-462.
[6]	张孟伟, 卢红.应用安罗替尼治疗小细胞肺癌伴脑转移患者一例[J]. 国际肿瘤学杂志, 2021, 48(2): 125-126.
[7]	施玥, 李晟, 冯继锋.急腹症风险下转移灶不可切除结直肠癌原发灶的处理方式选择[J]. 国际肿瘤学杂志, 2021, 48(11): 693-697.
[8]	马超, 蔡洪庆, 张敏杰, 叶士露, 孟肖利, 何洁, 万经海.肺癌脑转移瘤术后预后因素分析[J]. 国际肿瘤学杂志, 2020, 47(2): 77-81.
[9]	何剑波, 宁瑞玲, 蒋玮, 刘乾飞, 曾爱屏.重组人血管内皮抑制素优化给药策略联合化疗治疗晚期野生型NSCLC的临床观察[J]. 国际肿瘤学杂志, 2019, 46(8): 509-512.
[10]	易宗毕, 马飞, 徐兵河.乳腺癌脑转移的基因突变特征及靶向治疗[J]. 国际肿瘤学杂志, 2019, 46(6): 354-357.
[11]	董方, 薛金才, 王云生, 刘勤江.甲状腺癌外照射放射治疗的变迁[J]. 国际肿瘤学杂志, 2019, 46(11): 641-648.
[12]	郝志强,于德东,杨海祥,张润平,朱巍.埃克替尼联合放疗治疗非小细胞肺癌脑转移的疗效观察[J]. 国际肿瘤学杂志, 2018, 45(4): 202-205.
[13]	周金，武杰，张惠博，陈敏.老年晚期非小细胞肺癌患者的治疗[J]. 国际肿瘤学杂志, 2018, 45(12): 756-759.
[14]	陈域,纪洪辰,曹大勇,李霄.NRP-1在肝细胞癌组织中的表达及其临床意义[J]. 国际肿瘤学杂志, 2017, 44(6): 428-.
[15]	陈达雷,沈艳艳,林传琦,王晓慧,史豪,郭贵龙.乳腺癌术后局部-区域复发的治疗方案[J]. 国际肿瘤学杂志, 2017, 44(12): 929-932.